TherapeuticsMD, Inc.
TherapeuticsMD, Inc. Fundamental Analysis
TherapeuticsMD, Inc. (TXMD) shows moderate financial fundamentals with a PE ratio of 86.23, profit margin of 10.80%, and ROE of 1.11%. The company generates $0.0B in annual revenue with strong year-over-year growth of 35.25%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 57.1/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze TXMD's fundamental strength across five key dimensions:
Efficiency Score
WeakTXMD struggles to generate sufficient returns from assets.
Valuation Score
ModerateTXMD shows balanced valuation metrics.
Growth Score
ExcellentTXMD delivers strong and consistent growth momentum.
Financial Health Score
ExcellentTXMD maintains a strong and stable balance sheet.
Profitability Score
ModerateTXMD maintains healthy but balanced margins.
Key Financial Metrics
Is TXMD Expensive or Cheap?
P/E Ratio
TXMD trades at 86.23 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, TXMD's PEG of 0.52 indicates potential undervaluation.
Price to Book
The market values TherapeuticsMD, Inc. at 0.95 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -27.39 times EBITDA. This is generally considered low.
How Well Does TXMD Make Money?
Net Profit Margin
For every $100 in sales, TherapeuticsMD, Inc. keeps $10.80 as profit after all expenses.
Operating Margin
Core operations generate -97.10 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.11 in profit for every $100 of shareholder equity.
ROA
TherapeuticsMD, Inc. generates $0.78 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
TherapeuticsMD, Inc. generates strong operating cash flow of $2.07M, reflecting robust business health.
Free Cash Flow
TherapeuticsMD, Inc. generates strong free cash flow of $2.07M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.18 in free cash annually.
FCF Yield
TXMD converts 7.79% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
86.23
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.52
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.95
vs 25 benchmark
P/S Ratio
Price to sales ratio
9.31
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.24
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.46
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.01
vs 25 benchmark
ROA
Return on assets percentage
0.008
vs 25 benchmark
ROCE
Return on capital employed
-0.08
vs 25 benchmark
How TXMD Stacks Against Its Sector Peers
| Metric | TXMD Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 86.23 | 29.28 | Worse (Expensive) |
| ROE | 1.11% | 820.00% | Weak |
| Net Margin | 10.80% | -19743.00% (disorted) | Strong |
| Debt/Equity | 0.24 | 0.26 | Neutral |
| Current Ratio | 2.46 | 4.69 | Strong Liquidity |
| ROA | 0.78% | -17807.00% (disorted) | Weak |
TXMD outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews TherapeuticsMD, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-98.48%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
99.52%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
100.30%
Industry Style: Defensive, Growth, Innovation
High Growth